Literatura académica sobre el tema "Vitamin A Therapeutic use Tanzania"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Vitamin A Therapeutic use Tanzania".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Vitamin A Therapeutic use Tanzania"
1
Kisamo, Ombeni, Manase Kilonzi, Wigilya P. Mikomangwa, George M. Bwire, Hamu J. Mlyuka, Alphonce I. Marealle y Ritah F. Mutagonda. "The magnitude of prescribing medicines by brand names at Muhimbili National Hospital, Tanzania". Medicine Access @ Point of Care 4 (enero de 2020): 239920261990014. http://dx.doi.org/10.1177/2399202619900148.
Texto completoResumen
Background: Tanzania National Treatment Guidelines and National Therapeutic Committee circular of 2012 requires prescribers to prescribe medicines using their generic names as recommended by the World Health Organization. The implementation of the aforementioned recommendations by prescribers is not well documented in our settings. Therefore, this study aimed to explore the compliance on the use of generic names by prescribers at Muhimbili National Hospital. Methods: A descriptive cross-sectional study was conducted at Muhimbili National Hospital from January to May 2019 in both inpatient and outpatient pharmacy units. Data were analyzed using SPSS, version 23. Chi-square test was used to analyze proportions between the different variables of the study. A p-value for significance was <0.05. Results: Of 1001 prescriptions analyzed, 71.6% contained medicines prescribed using brand names. The mean (±standard deviation (SD)) number of medicines per prescription was 2.98 (±1.5). The most frequently prescribed medicines by brand names were a combination of vitamin and mineral supplements (34.4%) followed by antibiotics (26.7%). Medical doctors (25.6%) and medical specialists (21.6%) prescribed ⩾2 medicines using brand names per prescription compared to interns (15.0%) and residents (6.9%) ( p < 0.001). Conclusion: Prescribing medicines using brand names was highly observed in this study. Supplements and antibiotics were among the products that were highly prescribed using their brand names. Qualitative studies to explore reasons for brand name prescribing practices are recommended.
2
Mwita, Julius Chacha, Albertino Damasceno, Pilly Chillo, Okechukwu S. Ogah, Karen Cohen, Anthony Oyekunle, Endale Tefera y Joel Msafiri Francis. "Vitamin K-dependent anticoagulant use and level of anticoagulation control in sub-Saharan Africa: protocol for a retrospective cohort study". BMJ Open 12, n.º 2 (febrero de 2022): e057166. http://dx.doi.org/10.1136/bmjopen-2021-057166.
Texto completoResumen
BackgroundGiven that vitamin K-dependent anticoagulants (VKAs) will continue to be the primary anticoagulant in Africa for a long time, understanding the quality of anticoagulation services in the continent is vital for optimising the intended benefits. Notably, a few small studies have assessed the quality of anticoagulation in sub-Saharan Africa (SSA) countries. This study will describe the current VKA use and anticoagulation control among patients in selected SSA countries.Methods and analysisWe plan to review the 2019 anticoagulation data of a cohort of 800 random patients from 19 selected clinics in Botswana, the Democratic Republic of Congo, Ethiopia, Gambia, Ghana, Mozambique, Nigeria, Tanzania and South Africa. We expect at least one participating site to enrol 100 participants in each country. Eligible participants will be those on VKAs for at least 3 months and with at least four international normalised ratio (INR) results. We will document the indications, type and duration of VKA use, sociodemographic factors, coexisting medical conditions, concurrent use of drugs that interact with warfarin and alcohol and tobacco products. The level of anticoagulation control will be determined by calculating the time-in-therapeutic range (TTR) using the Rosendaal and the Percent of INR in TTR methods. A TTR of less than 65% will define a suboptimal anticoagulation control.Ethics and disseminationThis study was approved by the Ministry of Health and Wellness Ethics Committee (HPDME13/8/1) in Botswana and local research ethics committees or institutional review boards of all participating sites. As the study collects data from existing records, sites applied for waivers of consent. We will disseminate research findings through peer-reviewed scientific publications.
3
Haile, Zelalem T., Asli K. Teweldeberhan, Bhakti Chavan y John Francescon. "Hormonal contraceptive use and vitamin A deficiency among women in Tanzania". International Journal of Gynecology & Obstetrics 141, n.º 1 (15 de diciembre de 2017): 20–25. http://dx.doi.org/10.1002/ijgo.12396.
Texto completo
4
M. Fletcher, Jean, Sharee A. Basdeo, Aideen C. Allen y Padraic J. Dunne. "Therapeutic Use of Vitamin D and its Analogues in Autoimmunity". Recent Patents on Inflammation & Allergy Drug Discovery 6, n.º 1 (1 de enero de 2012): 22–34. http://dx.doi.org/10.2174/187221312798889239.
Texto completo
5
Zbinden, Gerhard. "THERAPEUTIC USE OF VITAMIN B1 IN DISEASES OTHER THAN BERIBERI". Annals of the New York Academy of Sciences 98, n.º 2 (15 de diciembre de 2006): 550–61. http://dx.doi.org/10.1111/j.1749-6632.1962.tb30576.x.
Texto completo
6
Carazo, Alejandro, Kateřina Macáková, Kateřina Matoušová, Lenka Kujovská Krčmová, Michele Protti y Přemysl Mladěnka. "Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity". Nutrients 13, n.º 5 (18 de mayo de 2021): 1703. http://dx.doi.org/10.3390/nu13051703.
Texto completoResumen
Vitamin A is a group of vital micronutrients widely present in the human diet. Animal-based products are a rich source of the retinyl ester form of the vitamin, while vegetables and fruits contain carotenoids, most of which are provitamin A. Vitamin A plays a key role in the correct functioning of multiple physiological functions. The human organism can metabolize natural forms of vitamin A and provitamin A into biologically active forms (retinol, retinal, retinoic acid), which interact with multiple molecular targets, including nuclear receptors, opsin in the retina and, according to the latest research, also some enzymes. In this review, we aim to provide a complex view on the present knowledge about vitamin A ranging from its sources through its physiological functions to consequences of its deficiency and metabolic fate up to possible pharmacological administration and potential toxicity. Current analytical methods used for its detection in real samples are included as well.
7
Donaldson, CJ y DJ Harrington. "Therapeutic warfarin use and the extrahepatic functions of vitamin K-dependent proteins". British Journal of Biomedical Science 74, n.º 4 (28 de junio de 2017): 163–69. http://dx.doi.org/10.1080/09674845.2017.1336854.
Texto completo
8
Thabet, Romany H., Adel A. Gomaa, Laila M. Matalqah y Erin M. Shalaby. "Vitamin D: an essential adjuvant therapeutic agent in breast cancer". Journal of International Medical Research 50, n.º 7 (julio de 2022): 030006052211138. http://dx.doi.org/10.1177/03000605221113800.
Texto completoResumen
Low serum levels of vitamin D have been reported as a risk factor for breast cancer. This narrative review provides an update on the impact of vitamin D on hormone receptors, notably estrogen receptor subunits, and gives insights on possible therapeutic interventions to overcome breast cancer. In addition, evidence that supports the beneficial use of vitamin D as adjuvant treatment of breast cancer is summarized. Vitamin D deficiency is significantly widespread in patients with triple-negative tumors. Several studies have observed a possible modulatory effect of vitamin D or its analogues on the expression of different hormone receptors in breast cancer and increased sensitivity to tamoxifen. Vitamin D possesses anti-inflammatory and immunomodulatory effects in patients with breast cancer, and the mechanism of action of vitamin D in patients with breast cancer is discussed. In conclusion, vitamin D appears to have a beneficial role in the prevention and management of breast cancer, however, large-scale, randomized controlled trials are needed to confirm the effects of vitamin D in breast cancer prevention or treatment.
9
Ræder, Helge, Nick Shaw, Coen Netelenbos y Robert Bjerknes. "A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet". European Journal of Endocrinology 159, suppl_1 (diciembre de 2008): S101—S105. http://dx.doi.org/10.1530/eje-08-0383.
Texto completoResumen
In hypophosphatemic rickets, there are both inherited and acquired forms, where X-linked dominant hypophosphatemic rickets (XLH) is the most prevalent genetic form and caused by mutations in the phosphate-regulating endopeptidase (PHEX) gene. XLH is associated with growth retardation and bone deformities. The renal tubular cells have an important role in calcium and phosphate metabolism, where the 1α-hydroxylase enzyme metabolizes the conversion of 25 (OH)-vitamin D to potent 1,25 (OH)2-vitamin D, whereas the sodium–phosphate transporter controls tubular phosphate reabsorption. The pathophysiological defect in XLH is speculated to cause an increase in a circulating phosphate regulating hormone termed phosphatonin (fibroblast growth factor 23 is the primary phosphatonin candidate), which leads to inhibition of 1α-hydroxylase, and simultaneously to inhibition of the sodium–phosphate transporter domain NPT2c leading to parathyroid hormone-independent phosphaturia. Hence, current treatment of XLH is 1,25 (OH)2-vitamin D or the vitamin D analog alfacalcidol and elementary phosphorus. Unfortunately, patients with XLH may develop nephrocalcinosis, secondary or tertiary hyperparathyroidism, and in some situations also hypertension and cardiovascular abnormalities. We describe a patient with XLH caused by a novel missense mutation in the PHEX gene, who on treatment with alfacalcidol and oral phosphate had normal growth and minimal bone deformities, but who subsequently developed moderate nephrocalcinosis, significant hyperparathyroidism, hypercalcemia, renal failure, and hypertension. We also report the use of the calcimimetic drug cinacalcet in the successful treatment of hypercalcemia and hyperparathyroidism.
10
Kurushina, O. V., A. E. Barulin y O. I. Agarkova. "Use of parenteral vitamin B complexes in treatment of polyneuropathy". Medical Council, n.º 18 (17 de noviembre de 2018): 62–66. http://dx.doi.org/10.21518/2079-701x-2018-18-62-66.
Texto completoResumen
The article considers the ethiological factors for the formation of such a widespread disease of the peripheral nervous system as polyneuropathy. The classification, modern approaches to the diagnosis of various types of diseases are presented. The authors emphasize on the therapeutic approaches to the treatment of such common forms as diabetic and alcoholic polyneuropathies. Particular attention is paid to the complex of B vitamins. The effectiveness and safety of the injectable form of vitamins for the therapy of polyneuropathies are demonstrated.
Tesis sobre el tema "Vitamin A Therapeutic use Tanzania"
1
Mwanri, Lillian. "Impact of vitamin A and iron on anaemia and cognitive functioning of anaemic school children in Tanzania". Title page, table of contents and summary only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phm994.pdf.
Texto completo
2
Potter, Kathleen. "The effects of long-term homocysteine-lowering treatment with folic acid, vitamin B6 and Vitamin B12 on vascular structure and function in stroke". University of Western Australia. School of Medicine and Pharmacology, 2009. http://theses.library.uwa.edu.au/adt-WU2010.0020.
Texto completoResumen
[Truncated abstract] An elevated total plasma homocysteine concentration (tHcy) is associated with an increased risk of myocardial infarction and ischemic stroke. Folic acid, vitamin B6 and B12 supplements significantly reduce tHcy even in people who are not overtly vitamin deficient. If homocysteine is a causal risk factor for atherothrombotic events, treatment with B-vitamins might prove a simple and cost-effective means to reduce cardiovascular risk. However, it remains unclear whether elevated tHcy causes atherosclerosis or is simply a risk marker. To prove that homocysteine is a modifiable risk factor for cardiovascular disease it is necessary to show that lowering tHcy reduces vascular risk. The aim of this study was to determine whether long-term homocysteine-lowering with B-vitamins would improve vascular structure and function in people with a history of stroke. This study was a cross-sectional sub-study of the Vitamins TO Prevent Stroke trial (VITATOPS), a multi-centre, randomised, double-blind, placebo-controlled clinical trial designed to test the efficacy and safety of B-vitamins (folic acid 2mg, vitamin B6 25mg and vitamin B12 0.5mg) in the prevention of vascular events in patients with a recent history of stroke or transient ischemic attack. 173 VITATOPS participants were recruited for the current study. Age, sex, stroke type, medications, cardiovascular risk factors and smoking history were recorded and blood pressure, height, weight, waist and hip girth were measured in all subjects at least two years after randomisation. ... After a mean treatment period of 3.9 ± 0.9 years, the subjects randomised to vitamin treatment had significantly lower tHcy than the subjects randomised to placebo (7.9mol/L, 95%CI 7.5, 8.4 versus 11.8mol/L, 95%CI 10.9, 12.8; p<0.001). There were no significant differences between groups in CIMT (0.84 ± 0.17mm vitamins versus 0.83 ± 0.18mm placebo; p=0.74) or FMD (median of 4.0%, IQR 0.9, 7.2, vitamins versus 3.0%, IQR 0.6, 6.6 placebo; p=0.48). Pooled estimates from the meta-analyses showed that B-vitamin treatment reduces CIMT by 0.10mm (95%CI 0.20, -0.01mm) and increases FMD by 1.4%, (95%CI 0.7, 2.2), although these estimates may have been influenced by positive publication bias. The improvement in FMD was significant in studies of less than eight weeks duration but not in studies with longer treatment periods. The association between tHcy and CIMT and FMD was eliminated by adjustment for renal function and long-term B-vitamin treatment did not alter the strong linear relationship between tHcy and cystatin C. Lowering tHcy did not alter arterial wall inflammation assessed by 18FDG-PET, although small subject numbers meant we were unable to exclude a minor treatment effect. Long-term homocysteine-lowering with B-vitamin treatment did not improve CIMT or FMD or reduce arterial wall inflammation in people with a history of stroke. The relationship between tHcy and these markers of vascular risk was eliminated by adjustment for renal function. Our data are consistent with the hypothesis that elevated tHcy is a risk marker for cardiovascular disease rather than a modifiable causal risk factor.
3
Stoll, Karin Elisabeth. "Nutrient supplementation and secondary metaolites in melanoma cells". Thesis, Rhodes University, 1994. http://hdl.handle.net/10962/d1004110.
Texto completoResumen
Considerable interest exists with regard to the putative therapeutic role of ascorbic acid in various conditions. A condition which has received much attention is cancer, as it is reported that ascorbic acid may be a prophylactic against cancer development. However, the actual involvement of ascorbic acid, an oxidizing/reducing agent, in the development and progression of tumours is presently a subject of much speculation. This study initially addressed the effect of ascorbic acid supplementation over a nutritional concentration range (0 - 100 μg/ml) on the in vitro growth of non-malignant LLCMK and malignant B16 cells. Ascorbic acid supplementation of these two cell types resulted in an overall decrease in the growth of both types of cells. The actual inhibitory mechanism of ascorbic acid on cell growth was not clear. Further study attempted to define and explain a mechanism responsible for this effect. Ascorbic acid has a role in the maintenance of tissue integrity and host defences, thus providing a rational basis for examining its relationship to cancer. Ascorbic acid is lcnown to be essential for the structural integrity of the intercellular matrix of the cells, the latter being a complex aqueous gel containing, amongst other compounds, fats and prostaglandins. Fats and prostaglandins have diverse effects on. membrane stability, enzyme activity and secondary messengers within cells. Hence, this study investigated the effect of ascorbic acid supplementation on certain enzymes and secondary metabolites within the cells, which had the potential to be involved in the control of cell growth. Throughout this study, emphasis was placed on the Bl6 melanoma cells as ascorbic acid supplementation did not significantly affect levels of secondary metabolites within the non-malignant LLCMK cells. Ascorbic acid supplementation of the B16 cells resulted in significant increases in adenylate cyclase activity and cyclic adenosine monophosphate levels, witb a significant decrease in Bl6 cell growth in that particular experiment. As cyclic adenosine monophosphate has a regulatory role in the cell cycle, this study suggested that the inhibitory effect of ascorbic acid supplementation on cell growth was mediated tbrough a final effect provided by the second messenger, cyclic adenosine monophosphate. However, clarification of tbe mechanism of tbe effect of ascorbic acid on adenylate cyclase activity was required. Hence, a further study investigated prostaglandin E₂ levels, as tbese affect adenylate cyclase activity. Prostaglandin E₂ levels were also found to be inversely related to Bl6 cell growth with ascorbic acid supplementation. It thus appeared tbat adenylate cyclase activity was dependent on prostaglandin E₂ levels in the B16 cells, and further study showed that tbis was indeed the case. Here, higher levels of prostaglandin E₂ supplementation of the Bl6 cells inhibited cell growth significantly and also significantly increased adenylate cyclase activity. Arachidonic acid is the precursor of prostaglandin E₂. In the presence of ascorbic acid supplementation, the percentage arachidonic acid composition of the Bl6 cells was inversely correlated with cell growth. Hence, prostaglandin E₂ levels in ascorbic acid supplemented B16 cells appeared dependent on tbe amount of precursor present. This was confirmed when Bl6 cells were supplemented with arachidonic acid. The latter had an inhibitory effect on Bl6 cell growth and also stimulated prostaglandin E₂ production. The cause of tbe inverse relationship between B16 cell growth and arachidonic acid composition with ascorbic acid supplementation was furtber investigated and found to be dependent on tbe uptake of arachidonic acid and other essential fatty acids from tbe medium. The enzymes phospholipase A₂ delta-5 and delta-6-desaturase, and elongase which could influence arachidonic acid levels were not affected to any extent by ascorbic acid supplementation and therefore did not influence the inverse relationship between B16 cell growth and arachidonic acid. Hence, it can be concluded that the effect of ascorbic acid supplementation on the BI6 cells is mediated, in part at least, by cyclic adenosine monophosphate. However, this is not the result of a direct effect of ascorbic acid supplementation. The initial effect of ascorbic acid supplementation concerns fatty acid - in particular arachidonic acid - uptake from the medium, with subsequent cascade effects On secondary metabolites, ultimately affecting the cellular levels of cyclic adenosine monophosphate.
4
Finch, Sarah L. "Postnatal vitamin D supplementation normalizes neonatal bone mass following maternal dietary vitamin D deficiency in the guinea pig". Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=100246.
Texto completoResumen
Since vitamin D deficiency is common at birth, the objective of this study was to test if postnatal vitamin D supplementation would normalize bone mineralization. Forty guinea pigs were randomized to receive a diet with or without vitamin D3 during pregnancy. Newborn pups were randomized to receive 10 IU of vitamin D3 or a placebo daily until d28. Measurements at birth and d28 included whole body and regional bone mass, osteocalcin and deoxypyridinoline, plus biomechanical testing of excised tibias and femurs. Offspring from deficient sows had lower body weight, whole body and tibia bone mineral content (BMC) and lower osteocalcin and biomechanical integrity. By d28 this group had lower whole body bone density and femur BMC, unless supplemented. Interactions with gender showed males continued to have low 25(OH)D despite supplementation. Therefore, neonates born to sows with dietary vitamin D deficiency require supplemental vitamin D to support normal bone mineral accretion.
5
Wu, Tianshu y 吴添舒. "A systematic review of vitamin D for prevention of acute lower respiratory infection among children". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193827.
Texto completoResumen
Objective:
Acute lower respiratory infection (ALRI) is the leading cause of mortality in pediatric group all around the world. Vitamin D has been demonstrated to play a possible role in the prevention of ALRI in children because of its physiological importance in the immune system. This systematic review aims to explore the protective role of vitamin D on ALRIs among children and its preventive effectiveness by synthesizing RCTs. And the other objective is to determine dosage of vitamin D with the best effect by investigating the association of different level of vitamin D supplementation with risk of ALRIs.
Methods:
Studies were searched through three databases PubMed, ISI Web of Knowledge and Cochran Central Register of Controlled Trials and Cochran Library databases among publication from April2003 to April 2013 with a combination of key terms. Inclusion and exclusion criteria were used to select studies. And then CONSORT guideline and JADAD scale were used to assess quality of these studies. Data on outcome measurements including health outcomes (e.g. incidence of pneumonia and influenza A, duration of recovery of pneumonia and bronchiolitis, the risk of relapse of pneumonia, the number of parent-reported ARIs); and surrogate outcomes (e.g. measuring scores of ATAQ test) were extracted and tabulated. The association with vitamin D level of risk of ALRIs were explored as well.
Results:
Eight RCTs were found to be relevant and adopted in this systematic review of the 796 identified articles in English or Chinese. The findings were mixed, but most studies suggested vitamin D supplementation reduced risk or illness duration of ALRIs significantly among children with different levels of vitamin D deficiency. Four studies suggested statistically significant risk reduction on incidence of repeat pneumonia (by29%, 95%CI 6% to 46%), parent-reported ARIs (by 48%, 95%CI 11% to 69), influenza A (by 42%, 95%CI 1% to 66%), and asthma exacerbation triggered by ALRIs (P= 0.029), while one study showed an insignificant outcome. For recovery events and hospitalization of ALRIs, three studies suggested statistically significant reduction on recovery time from pneumonia (P= 0.008), severe asthma (P= 0.004) and bronchiolitis (P< 0.05), and two studies suggested significant decrease on duration of hospitalization for bronchiolitis (P< 0.05) and pneumonia (P= 0.005). The increasing changes in serum 25(OH)D were consistent with the significant difference of ALRIs events between intervention and control groups.
Conclusion:
Overall, the evidence is insufficient to conclude that vitamin D supplementation is beneficial to all kinds of children in preventing or assistant treating ALRIs. More number of high quality, large scale and unbiased RCTs should be conducted to confirm the effectiveness of vitamin D among children in Hong Kong and different areas in mainland China.published_or_final_version
Public Health
Master
Master of Public Health
6
Halliwell, Celeste y University of Lethbridge Faculty of Arts and Science. "Dietary choline and vitamin/mineral supplement for recovery from early cortical injury". Thesis, Lethbridge, Alta. : University of Lethbridge, Faculty of Arts and Science, 2003, 2003. http://hdl.handle.net/10133/222.
Texto completoResumen
Early cortical injury has been attributed to the consequential effects of various factors, such as alcohol, drug addiction, smoking, and inadequate nutrient intakes during periods of pregnancy and lactation, or delivery of infants by forceps, and premature deliveries. These are only a few examples of circumstances, or "injury", that may result in disorders ranging from mild learning difficulties to aggressive behaviour. Injury to the cortex during the early years of development has been know to result in poor behavioural outcome into adulthood. Presently, the most common form of treatment includes a pharmacological agent, which may be accompanied with behavioral modification therapies supported by families. As an alternative form of therapy towards the treatment of early cortical injury, choline and a vitamin and mineral supplement (EM Power+) were used to determine the possibilities of nutrition intervention in an animal model. The injuries were incurred by aspiration lesion at days three, (Exp.1) and four, (Exp.2) and lesions were localized to the midline medial frontal cortex in some rats, while a different group of rats received lesions in the posterior parietal cortex. The pre-and postnatal choline treated animals showed favorable results for the medial frontal lesions, and the postnatal vitamin supplement treated animals showed favorable results for treatment in both medial frontal and posterior parietal lesions. All animals were tested in adulthood indicating that nutrition intervention is very beneficial for alleviating some of the functional deficits commonly seen from early cortical injury.xiv, 191 leaves : ill. ; 28 cm.
7
Hautea, Rhea P. "Vitamin D- induced down regulation of RAD51 in head and neck squamous cell carcinoma (HNSCC), In Vitro and In Vivo". Scholarly Commons, 2011. https://scholarlycommons.pacific.edu/uop_etds/786.
Texto completoResumen
The active form of Vitamin D (VD3) has been shown to induce pro-apoptotic and anti-proliferative effects in several mammalian cancer cell types. The molecular mechanisms of tumor suppression, however, are not clearly understood. Previous research has shown that head and neck squamous cell carcinoma (HNSCC) responds to VD3. This thesis used both in vivo and in vitro models to examine the effect of VD3 in HNSCC. Former work in the Albala laboratory showed that hamsters that received systemic VD3 and topical treatment of 7,12-dimethylbenz(a)anthracene (DMBA) to the buccal pouch showed no or delayed carcinogenesis over the 14-week study compared to DMBA-only treated hamsters. This research further investigated the effect of VD3 in this hamster model. Using immunohistochemical (IHC) and western blot analysis, we demonstrate that systemic application of VD3to hamsters downregulates Rad51 expression in the buccal pouch and hinders the onset of tumor formation. Rad51 is a protein that plays a critical role in cell proliferation and homologous recombinational DNA repair. In the in vitro model, we show that Rad51 expression decreased in response to 100nM VD3 in HNSCC cell lines. The dose and time-dependence of VD3 on these cells was also examined. Western blot analysis and comet assay investigations confirmed that the SCC25 cell line is most sensitive to 100nM VD3 than to other doses tested, and that VD3 impairs the DNA-damage response. SiRNA and co-immunoprecipitation studies examined the potential of Chk 1 and p38 MAPK as upstream regulators of Rad51. Rad51 protein expression was found to be associated with early carcinogenesis from HNSCC cancer patients using IHC studies of human carcinomas from the oral cavity. This study focused on further identifying the role of Rad51 in response to VD3 in HNSCC.
8
Clarke, Michael William. "Vitamin E metabolism in humans". University of Western Australia. School of Medicine and Pharmacology, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0191.
Texto completoResumen
[Truncated abstract] Vitamin E is comprised of a family of tocopherols (TOH) and tocotrienols. The most studied of these is [alpha]-tocopherol ([alpha]-TOH), as this form is retained within the body and any deficiency of vitamin E is corrected with this supplement. [alpha]-TOH is a lipid-soluble antioxidant required for the preservation of cell membranes and potentially acts as a defense against oxidative stress. Individuals who have a primary vitamin E deficiency such as low birth weight infants, secondary vitamin E deficiency due to fat malabsorption such as in abetalipoproteinaemia, or a genetic defect in TOH transport require supplementation. There is debate as to whether vitamin E supplementation in other patient groups is required. Vitamin E supplementation has been recommended for persons with FHBL, a rare disorder of lipoprotein metabolism that leads to low serum [alpha]-TOH and decreased LDL cholesterol and apolipoprotein B concentrations. We examined the effect of truncated apoB variants on vitamin E metabolism and oxidative stress in persons with heterozygous FHBL. We used HPLC with electrochemical detection to measure [alpha]- and [gamma]-TOH in serum, erythrocytes, and platelets, and GC-MS to measure urinary F2-isoprostanes and TOH metabolites as markers of oxidative stress and TOH intake, respectively. Erythrocyte [alpha]-TOH was decreased, but we observed no differences in lipid-adjusted serum TOHs, erythrocyte [gamma]-TOH, platelet [alpha]- or [gamma]-TOH, urinary F2-isoprostanes, or TOH metabolites. Taken together, our findings do not support the recommendation that persons with heterozygous FHBL should receive vitamin E supplementation. ... Sesame lignans are natural components of sesame seed oil and there is evidence that these lignans can inhibit CYP450 enzymes, in particular, those responsible for vitamin E metabolism. We hypothesised that sesame seed ingestion would increase serum [gamma]-TOH, lower plasma lipids and inhibit platelet function in human subjects with at least one cardiovascular risk factor. We used HPLC with electrochemical detection to measure [alpha]- and -TOH in serum and GC-MS to measure F2-isoprostanes and TOH metabolites as markers of oxidative stress and TOH intake, respectively. We used high-sensitive C-reactive protein as a measure of systemic inflammation. Platelet function was assessed using the PFA-100 platelet aggregation assay. Although serum [gamma]-TOH increased by 17%, we observed no effect on lipid metabolism, markers of inflammation, oxidative stress or platelet function following treatment with ~25 g/day sesame seeds for five weeks. Our findings challenge the hypothesis that sesame seed ingestion provides beneficial cardiovascular effects. In summary, we have studied the metabolism and transport of both [alpha]- and [gamma]-TOH in humans to evaluate the requirements for supplementation and the effects of vitamin E on platelet function and CYP3A4 activity. Specialised techniques using HPLC were developed to measure serum and cellular TOH concentrations both in supplemented and un-supplemented individuals. We also used GCMS to provide a sensitive, accurate assessment of TOH metabolites and midazolam pharmacokinetics in humans after vitamin E supplementation. We have examined the role vitamin E has on important biochemical endpoints, with emphasis on the implications for TOH supplementation in subjects at risk of CVD.
9
Milliken, Erin L. "USE OF A TRANSGENIC MOUSE MODEL OF OVARIAN HYPERSTIUMLUATION TO IDENTIFY THERAPEUTIC TARGETS AND MECHANISMS IN HORMONE-INDUCED MAMMARY CANCER". Case Western Reserve University School of Graduate Studies / OhioLINK, 2005. http://rave.ohiolink.edu/etdc/view?acc_num=case1121273034.
Texto completo
10
Murphy, Stephanie A. "Effects of selenium and vitamin B-6 on growth of chemically- induced transplanted tumors in BALB/c inbred mice". Thesis, Virginia Tech, 1989. http://hdl.handle.net/10919/43906.
Texto completoResumen
Male weanling inbred, mice were inoculated with
fibrosarcoma cells (hindquarter) originally produced by 2-methylcholanthrene. Before inoculation, mice were randomly divided into three groups of 24 and one of 12
(control). After a one week acclimation period, each group was fed a diet containing either suboptimal vitamin B-6, 0.5 mg/kg diet; adequate, 7.0 mg/kg diet; or excess, 100 mg/kg diet. Controls were fed the adequate vitamin. B-6 diet. Twenty-four hours after
tumor cell inoculation, a series of sodium selenite injections (0.5 μg/.10 mL) were given to half of each treatment group and all controls. Mice were sacrificed
two wk after tumor inoculation. Tumors were excised and weighed. Selenium-treated mice had significantly smaller tumors as compared to untreated mice regardless
of vitamin B-6 treatment. The smallest tumors were
found in the selenium-treated group maintained on
adequate B-6, while the largest tumors were developed
by mice on the excess B-6 diet without selenium treatments.
All groups had similar blood selenium levels as
measured by gas chromatography. Tumor selenium levels,
analyzed by atomic absorption, were significantly
higher for untreated groups than selenium-treated
groups (larger tumor size). The excess and adequate
vitamin B-6 selenium-treated groups had significantly
lower tumor selenium levels than the adequate vitamin
B-6 untreated group. Plasma pyridoxal phosphate
(concentrations) determined radiometrically and tumor
vitamin B-6 levels determined microbiologically, related directly to dietary treatments. Sodium selenite
injections and adequate vitamin B-6 diets reduced the
size of fibrosarcomas in BALB/c inbred mice.Master of Science
Libros sobre el tema "Vitamin A Therapeutic use Tanzania"
1
Pedersen, Stephanie. Vitamin D: Maximizing minerals. New York: Dorling Kindersley, 2000.
Buscar texto completo
2
Jean, Pamplin, ed. Vitamin B6 therapy. Garden City Park, N.Y: Avery Pub. Group, 1999.
Buscar texto completo
3
Books, Prevention Magazine Health. Vitamin prescriptions for healing. Emmaus, PA: Rodale Press, 1997.
Buscar texto completo
4
Pedersen, Stephanie. Vitamin C: Building flexibility & fighting infection. New York: Dorling Kindersley Pub., 2000.
Buscar texto completo
5
Pedersen, Stephanie. Vitamin E: Anti-aging & anti-oxidant. New York: Dorling Kindersley Pub., 2000.
Buscar texto completo
6
Vitamin C, the master nutrient. New Canaan, Conn: Keats Pub., 1991.
Buscar texto completo
7
Pedersen, Stephanie. Vitamin B: Balancing body & mind. New York: DK, 2000.
Buscar texto completo
8
Pedersen, Stephanie. Vitamin B: Balancing body & mind. New York: Dorling Kindersley Pub., 2000.
Buscar texto completo
9
Hoffer, Abram. Vitamin B-3, schizophrenia: Discovery, recovery, controversy. Kingston, Ont: Quarry Press, 1998.
Buscar texto completo
10
Primal panacea: By Thomas E. Levy. Henderson, NV: MedFox Pub.,2011., 2011.
Buscar texto completoCapítulos de libros sobre el tema "Vitamin A Therapeutic use Tanzania"
1
CARPENTER, THOMAS O. y KARL L. INSOGNA. "The Hypocalcemic Disorders: Differential Diagnosis and Therapeutic Use of Vitamin D". En Vitamin D, 1049–63. Elsevier, 2005. http://dx.doi.org/10.1016/b978-012252687-9/50067-x.
Texto completo
2
M. Jasim, Adnan y Mohammed J. Jawad. "Pharmaceutical Applications of Vitamin E TPGS". En Vitamin E in Health and Disease - Interactions, Diseases and Health Aspects [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.97474.
Texto completoResumen
D-tocopheryl polyethylene glycol succinate (Vitamin E TPGS) has been approved as a safe pharmaceutical adjuvant by FDA, and several drug delivery systems (DDS) based on TPGS have been developed. TPGS properties as a P-gp inhibitor, solubilizer/absorption and permeation enhancer in drug delivery and TPGS-related formulations such as nanocrystals, nanosuspensions, tablets/solid dispersions, vaccine system adjuvant, nutritional supplement, film plasticizer, anticancer reagent, and so on, are discussed in this review. Consequenly, TPGS can inhibit ATP-dependent P-glycoprotein activity and act as a potent excipient that promotes the efficiency of delivery and the therapeutic effect of drugs. Inhibition of P-gp occurs through mitochondria-dependent inhibition of the P-gp pump. Many of the latest studies address the use of TPGS for many poorly water-soluble or permeable drugs in the manufacture of nanodrugs or other formulations. In addition, it has been reported that TPGS shows a robust improvement in chylomicron secretion at low concentrations and improves intestinal lymphatic transport, which would also boost the potential of drug absorption. It also indicates that there are still many problems facing clinical translation of TPGS-based nanomedicines, requiring a more deep evaluation of TPGS properties and a future-based delivery method.
3
Brody, David L. "General Treatment Strategies". En Concussion Care Manual, editado por David L. Brody, 17–18. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780190054793.003.0006.
Texto completoResumen
Top 10 General Priorities: (1) Do one thing at a time. (2) Stop or taper impairing medications before adding new ones. (3) Minimize side effects of medications. (4) Offer rehabilitative therapy and lifestyle modification interventions as well as medications. (5) Educate and comfort. (6) Give an honest prognosis with a positive spin. (7) Use a healthy dose of Vitamin P (“placebo”) in an appropriate way. (8) Under the right circumstances, it’s OK to use a big dose of Vitamin S (the “therapeutic scare”) also. (9) Offer follow-up and appropriate referrals. (10) Support the family.
4
Brody, David L. "General Treatment Strategies". En Concussion Care Manual, 11–12. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199383863.003.0005.
Texto completoResumen
This chapter discusses the top 10 general priorities in treating concussion: (1) Do one thing at a time. (2) Stop or taper impairing medications before adding new ones. (3) Minimize side effects of medications. (4) Offer rehabilitative therapy and lifestyle modification interventions as well as medications. (5) Educate and comfort. (6) Give an honest prognosis with a positive spin. (7) Use a healthy dose of “Vitamin P” (“placebo”) in an appropriate way. (8) Under the right circumstances, it’s ok to use a big dose of “Vitamin S” (the “therapeutic scare”) also. (9) Offer follow-up and appropriate referrals. (10) Support the family.
5
Grossman, Lewis A. "The Spirit of the ’70s". En Choose Your Medicine, 138–61. Oxford University Press, 2021. http://dx.doi.org/10.1093/oso/9780190612757.003.0007.
Texto completoResumen
This chapter explores how in the 1970s, freedom of therapeutic choice advocacy, previously the domain of right-wing extremists, became bipartisan and mainstream. It examines how various cultural trends contributed to this trend, including a loss of trust in orthodox medicine, government, and other establishment institutions; a “rights revolution” (including the rise of patients’ rights); and the emergence of the women’s health movement. The chapter shows how Americans’ use of alternative remedies surged during this period and discusses in detail two 1970s social movements in favor of alternative treatments: a successful rebellion against the FDA’s attempt to regulate vitamin and mineral supplements more stringently and a campaign to resist the FDA’s ban on Laetrile, an alternative cancer treatment derived from apricot pits. The chapter also describes how American courts briefly seemed prepared to elaborate the holding of Roe v. Wade into a generalized right to freedom of therapeutic choice.
6
Lip, Gregory Y. H. "Stroke risk factors and risk stratification in atrial fibrillation". En ESC CardioMed, 2182–85. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0513.
Texto completoResumen
Atrial fibrillation increases the risk of stroke, and the more common and validated risk factors have been used to formulate stroke risk stratification schemes, but the default position is to offer stroke prevention to all patients with atrial fibrillation unless they are shown to be at low risk. The use of the CHA2DS2-VASc score is recommended for stroke risk stratification in guidelines. Decision-making for stroke prevention should apply the simple ‘atrial fibrillation three-step’ patient pathway. Step 1 is to initially identify ‘low-risk’ patients (CHA2DS2-VASc 0 in males, 1 in females) who do not need antithrombotic therapy; step 2 is to offer stroke prevention (i.e. oral anticoagulation) to those with at least one stroke risk factor; step 3 is to decide between a vitamin K antagonist (with good time in therapeutic range at >70%) or a non-vitamin K antagonist oral anticoagulant, using the SAMe-TT2R2 score. This simple streamlined practical approach will help risk stratification and treatment decision-making.
7
Zhaku, Vegim, Ashok Agarwal, Sheqibe Beadini, Ralf Henkel, Renata Finelli, Nexhbedin Beadini y Sava Micic. "Male Infertility, Oxidative Stress and Antioxidants". En Vitamin E in Health and Disease - Interactions, Diseases and Health Aspects [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.98204.
Texto completoResumen
Within the male reproductive system, oxidative stress (OS) has been identified as prevailing etiology of male infertility. The effects of reactive oxygen species (ROS) on male fertility depend on the dimensions, “modus operandi” of the ROS and the oxido-reduction potential (ORP) of the male reproductive tract. Hereupon, for an adequate response to OS, the cells of our body are endowed with a well-sophisticated system of defense in order to be protected. Various antioxidant enzymes and small molecular free radical scavengers, maintain the delicate balance between oxidants and reductants (antioxidants), crucial to cellular function and fertility. Therapeutic use of antioxidants is an optimal and coherent option in terms of mitigating OS and improving semen parameters. Therefore, recognizing and managing OS through either decreasing ROS levels or by increasing antioxidant force, appear to be a requesting approach in the management of male infertility. However, a clear defined attitude of the experts about the clinical efficacy of antioxidant therapy is still deprived. Prominently, antioxidant such as coenzyme Q10, vitamin C and E, lycopene, carnitine, zinc and selenium have been found useful in controlling the balance between ROS production and scavenging activities. In spite of that, healthy lifestyle, without smoke and alcohol, everyday exercise, reduction of psychological stress and quality well-designed meals, are habits that can overturn male infertility.
8
Yesilkaya, Burcu. "Clinical Application of New Possible Biomarkers in the Assessment and Monitoring of Nutritional Status". En Biomarkers in Medicine, 611–25. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815040463122010027.
Texto completoResumen
Nutrition is directly related to human health. It is very critical to determinethe nutritional status to prevent or diagnose diseases and create the right treatmentplans. The determination of the nutritional status provides an early diagnosis of growthand development retardation such as malnutrition. It also plays a major role inpreventing diseases that may be caused by vitamin and mineral deficiencies. It helps inthe surveillance of one of the world's most serious health problems, namely “obesity.”Different ways can be used to assess nutritional status. One of the best ways to assessthe nutritional and health status is to use biomarkers. A biomarker is a substance whosedetection indicates a specific disease state or a response to a therapeutic intervention.Biomarkers are used to detect nutrient consumption and deficiencies as early aspossible, enabling early intervention for metabolic problems. Biomarkers also allow thevisualization of diseases that a person might develop or potentially have with a sample,such as blood, tissue, and urine, from the person. Health interventions such asnutritional advice will preserve health or promote rapid recovery. In this chapter, thetopic of biomarkers related to nutrition and nutrient deficiencies is discussed. Theexistence of new possible biomarkers is also reviewed.
9
van Mens, Thijs E. y Saskia Middeldorp. "Management of pulmonary embolism in pregnancy". En ESC CardioMed, 2786–90. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0665.
Texto completoResumen
Pulmonary embolism, although rare, is a leading cause of maternal mortality. There is no strong evidence base for the diagnosis and management of pregnancy-related pulmonary embolism, hampering firm recommendations. In women with a suspicion of pulmonary embolism, the diagnosis is confirmed in 1 in 25–30 women only. However, imaging is always necessary to exclude pulmonary embolism, as no clinical decision rules or D-dimer-based strategies have been validated in pregnancy. Computed tomography pulmonary angiography and pulmonary scintigraphy are both suitable modalities, unless deep vein thrombosis is confirmed by compression ultrasonography of lower limb veins. Low-molecular-weight heparin (LMWH) in therapeutic doses is the treatment of choice during pregnancy, and anticoagulation should be continued until 6 weeks after delivery with a minimum total duration of 3 months. Use of LMWH or vitamin K antagonists does not preclude breastfeeding. Whether dosing should be based on weight or anti-Xa levels is unknown, and practices differ between centres. Management of delivery, including the type of anaesthesia if deemed necessary, requires a multidisciplinary approach, and several options are possible, depending on local preferences and patient-specific conditions. Prevention of pulmonary embolism with LMWH is indicated in all postpartum women with a history of venous thromboembolism, and in most women also during pregnancy.
Actas de conferencias sobre el tema "Vitamin A Therapeutic use Tanzania"
1
Bobeck, Elizabeth. "Bioactive lipids and related nutrients in companion animal and poultry diets for reducing inflammation and improving immunity". En 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/vqxl3869.
Texto completoResumen
Beyond meeting nutritional requirements for growth and maintenance, select dietary ingredients can have additional effects, intended or not, on animal physiology and immune function. Diets can be enriched to benefit the animal, and a dual benefit can be achieved in the case of enriching animal products for the downstream human consumer. Many immune-altering nutrients are fat-soluble, including Vitamin E and D. Importantly, dietary lipids themselves can impact immune function; therefore, a focused and intentional selection of specific dietary fats, specifically omega-3 polyunsaturated fatty acids (PUFA), is one method to alter inflammatory cascades in animals consuming the diet. Examples of other related ingredients to which the immune system is responsive include zinc and probiotics. While work in human, livestock, and companion animal models is working to identify therapeutic inclusion rates for these nutrients and ingredients, it should be noted that physiological alterations are seen in both over and under-inclusion and are nutrient-specific. For example, inclusion above currently recommended levels may optimize immune function and reduce inflammation in the case of vitamin D or omega-3 PUFA, while for zinc, additional pharmacological supplementation above requirements may inhibit immune function. Importantly, when a diet is formulated to reduce overall systemic inflammation, it must be considered that important “background†functions of the immune system, including monitoring for and clearing pathogenic microbial populations, may be down-regulated due to a general reduction in immune reactivity. Continued work to understand how diet and nutrition impact immunity, and how to balance inflammation through nutrition, is an area of active research and will inform downstream users how to best use data to impact consumers of that feed in desirable ways.
2
Costa, Virgínia Madureira, Iris Maria de Miranda Correia, Laís Michela Rodrigues Sales Arruda, José Leandro da Silva Menezes Diniz, Maria Tereza Corrêa de Araújo, Maysa Aiany Dias de Sousa Alves, Maria Fernanda Paes de Assis et al. "The effectiveness of using thiamine in the Wernicke-Korsakoff syndrome". En XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.380.
Texto completoResumen
Introduction: The Wernicke-Korsakoff syndrome is a condition caused by thiamine (vitamin B1) deficiency in the brain, being a debilitating and potentially fatal factor. It is characterized by a classic triad: delirium, ophthalmoparesis and ataxia. Objectives: Analyze the possible effectiveness of using thiamine in the prognostic change of patients with the syndrome, as well as the ideal dose and identification of possible secondary outcomes of the use of thiamine. Methods: A systematic review made in March 2021, included studies published between 2011-2021. The descriptors selected according to the MeSH platform, were inserted in the SCIELO, Lilacs and PubMed databases, resulting in a total of 323 studies, of which only 8 were selected. Results: Among the 8 evaluated articles, 5 reinforce the effectiveness of thiamine therapy, with prognostic changes in those patients, and only 4 of these studies describe their clinical evolution, showing mostly a gradual regression of the ocular manifestations and ataxia, while neurological symptoms tend to develop later. Thus 62,5% of the articles show improvement of patients with these therapeutics. Other studies do not refer to the prognosis after the institution of the treatment. About the dose, it was observed that the therapeutic effectiveness was related to higher doses of thiamine. Conclusion: Most of the analyzed studies were favorable to the hypothesis of the early use of thiamine in regression of the symptoms. Regarding the most effective dose, the topic still needs studies with high scientific evidence, as it hasn’t yet been thoroughly discussed in the literature.